Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC SODIUM AND MISOPROSTOL versus XALATAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC SODIUM AND MISOPROSTOL versus XALATAN.
DICLOFENAC SODIUM AND MISOPROSTOL vs XALATAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Misoprostol is a synthetic prostaglandin E1 analog that replaces protective prostaglandins in the gastric mucosa, reducing gastric acid secretion and increasing mucus and bicarbonate production.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing the outflow of aqueous humor through the uveoscleral pathway.
Diclofenac sodium 50 mg/misoprostol 200 mcg orally twice daily with food for osteoarthritis and rheumatoid arthritis; diclofenac sodium 75 mg/misoprostol 200 mcg orally twice daily for rheumatoid arthritis.
One drop (1.5 mg/mL) in the affected eye(s) once daily in the evening.
None Documented
None Documented
Diclofenac: Terminal t1/2 ~1-2 h (short, requiring frequent dosing). Misoprostol: Terminal t1/2 ~20-40 min (rapidly de-esterified to active misoprostol acid, with acid t1/2 ~20-30 min).
Terminal elimination half-life of latanoprost acid is approximately 17 minutes; clinically, intraocular pressure reduction persists for 24 hours due to long receptor residence time.
Diclofenac: ~65% renal (primarily as glucuronide conjugates, with <1% unchanged), ~35% biliary/fecal. Misoprostol: >80% renal as inactive metabolites.
Renal (approximately 50% as metabolites, <1% as unchanged drug); biliary/fecal (remainder).
Category D/X
Category C
Prostaglandin Analog
Prostaglandin Analog